All too often, pharmaceutical capital investments are benchmarked against initial concept baselines that are rooted in immature assumptions, data not truly comparable, or not using best practices to develop a solid baseline range. Turner & Townsend Taurus has decades of pharmaceutical program experience ranging from troubled projects to successful ones, with a deep library worth of digitized benchmarking data. In this presentation we will demonstrate, through our proven early planning approach combining technology, people, and past market data, how effective early concept planning and estimating allows your capital program to baseline to ensure a proper roadmap to managing risk throughout your program. We will take you through our TIC (TARGET, IMPROVE, CONTROL) methodology to developing data driven conceptual estimates and schedules that integrate the whole program from concept through regulatory submission. We will provide a detailed review of how we utilize our state-of-the-art benchmarking tool, the HIVE, and bring our industry experts to show how our experience intersects with real world tools and capability to deliver world class up front program planning. The participants will come away with an understanding of the needed steps to utilize technology, industry data and a proven plan to develop a solid up-front baseline.